2 weeks Ago By ABMN Staff
Renaissance Technologies LLC lowered its stake in Mereo BioPharma Group plc ( NASDAQ:MREO – Free Report ) by 8.9% during the 4th quarter, Holdings Channel reports. The firm owned 1,189,471 shares of the company’s stock after selling 115,900 shares during the quarter.
Renaissance Technologies LLC’s holdings in Mereo BioPharma Group were worth $4,163,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors have also made changes to their positions in the company. Newbridge Financial Services Group Inc.
purchased a new stake in shares of Mereo BioPharma Group in the fourth quarter worth about $37,000. Sheets Smith Investment Management bought a new position in shares of Mereo BioPharma Group during the 4th quarter valued at approximately $59,000. Avanza Fonder AB bought a new position in shares of Mereo BioPharma Group during the 4th quarter valued at approximately $69,000.
Golden State Equity Partners grew its holdings in shares of Mereo BioPharma Group by 247.7% in the fourth quarter. Golden State Equity Partners now owns 22,600 shares of the company’s stock valued at $79,000 after purchasing an additional 16,100 shares in the last quarter.
Finally, PFG Investments LLC increased its position in Mereo BioPharma Group by 132.0% in the fourth quarter. PFG Investments LLC now owns 39,433 shares of the company’s stock worth $138,000 after purchasing an additional 22,433 shares during the last quarter.
Institutional investors own 62.83% of the company’s stock. Analyst Ratings Changes Several equities research analysts have weighed in on MREO shares.
Lifesci Capital began coverage on Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective on the stock.
Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Wednesday, April 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.
00 price target on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. Finally, JPMorgan Chase & Co. assumed coverage on Mereo BioPharma Group in a research report on Thursday, March 27th.
They issued an “overweight” rating and a $7.00 price objective on the stock. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company.
Based on data from MarketBeat.com, Mereo BioPharma Group has an average rating of “Buy” and an average target price of $7.71.
Mereo BioPharma Group Price Performance MREO stock opened at $2.33 on Tuesday. Mereo BioPharma Group plc has a 1-year low of $1.
58 and a 1-year high of $5.02. The business has a 50-day moving average price of $2.
38 and a 200 day moving average price of $3.21. The company has a market capitalization of $370.
47 million, a P/E ratio of -38.83 and a beta of 0.71.
Mereo BioPharma Group ( NASDAQ:MREO – Get Free Report ) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.
02 by ($0.03). On average, analysts anticipate that Mereo BioPharma Group plc will post -0.
03 earnings per share for the current fiscal year. Mereo BioPharma Group Company Profile ( Free Report ) Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Featured Articles Want to see what other hedge funds are holding MREO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mereo BioPharma Group plc ( NASDAQ:MREO – Free Report ). Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.
com's FREE daily email newsletter ..
